Pharmacological effect of olive-derived polyphenols in osteoarthritis.
Abstract
Osteoarthritis (OA) is the most prevalent disorder of articulating joints and a leading cause of disability in humans, affecting half of the world's population aged 65 years or older. Articular cartilage and synovial tissue from OA patients show an overactivity of the membrane channel protein connexin43 (Cx43) and accumulation of senescent cells associated with disrupted tissue regeneration. We have recently demonstrated the use of the Cx43 as an appropriate therapeutic target to halt OA progression by decreasing the accumulation of senescent cells and by triggering redifferentiation of osteoarthritic chondrocytes (OACs) into a more differentiated state, restoring the fully mature phenotype and cartilage regeneration. In this study we have found that small molecular polyphenols derived by olive extracts target Cx43 and senescence in OACs, synovial and bone cells from patients and in human mesenchymal stem cells (hMSCs). Our results indicate that these small molecules including oleuropein regulate the promoter activity of Cx43 gene. The downregulation of Cx43 expression by oleuropein reduce gap junction intercellular communication, cellular senescence in chondrocytes and enhance the propensity of hMSCs to differentiate into chondrocytes and bone cells, reducing adipogenesis. In concordance with these results, these small molecules reduce Cx43 and decrease Twist-1 activity leading to redifferentiation of OACs, which restores the synthesis of cartilage ECM components (Col2A1 and proteoglycans) and reduces inflammatory and catabolic factors IL-1ß, IL-6, COX-2 and MMP-3 and cellular senescence orchestrated by p53/p21 together with the synthesis of SASP via NF-kB. Altogether, our results demonstrate the use of the olive-derived polyphenols such as oleuropein as potentially effective therapeutic agents to enhance the efficacy of hMSC therapy and to induce a pro-regenerative environment in OA patients by restoring cellular phenotype and clearing out senescent cells in joint tissues in order to stop or prevent the progression of the disease.
Introduction.
Osteoarthritis (OA) is the most common degenerative joint disorder characterised by progressive degeneration of synovial joints that lead to limited mobility and pain. OA is the major cause of disability with a major socio-economic impact, which affects an increasing number of the ageing population 1 . Cartilage damage is the most typical sign of OA. Yet, this condition also affects the whole joint including bone, synovium, muscles, tendons and ligaments 2 . Articular cartilage from patients with OA shows an accumulation of dedifferentiated and senescent cells 3-6 together with an increase in the production of pro-inflammatory cytokines such as IL-1ß and catabolic enzymes (matrix metalloproteinases (MMPs) and aggrecanases) that lead to the breakdown of cartilage extracellular matrix (ECM) 7 . The prevalence of OA is rising worldwide 8 and the aetiology is still under study, with new insights into molecular mechanisms involved in OA progression beginning to open new possibilities to restore phenotypic stability of articular chondrocytes and to develop new approaches in order to promote cartilage repair and restore normal joint function in OA patients 9-12 .
Interestingly and consistent with other wound-healing disorders, osteoarthritic cartilage and synovial tissue from OA patients contain high levels of the gap junction protein connexin43 (Cx43). Therapeutic approaches targeting Cx43 are showing promise in benefiting several age-related and chronic degenerative diseases by modulating tissue regeneration, inflammation and response to injury 13, 14 . Cx43 is linked to regeneration and response to injury through several different mechanisms, acting as a brake in wound healing in skin 14, 15 , cartilage 4, 16, 17 and neurodegenerative disorders such as Alzheimer´s disease 18 . Cx43 belongs to the integral membrane protein family called connexins which form hemichannels and gap junctions (GJs) that enable direct communication between neighbouring cells by interchanging electrical, metabolic and signalling molecules such as IP3, cAMP, ions, glutathione or siRNAs 19, 20 . Additionally, these channel proteins act as scaffold proteins or signalling hubs via their cytoplasmic domains 4, 21 , regulating different key signalling pathways independently of their channel activity 4, [22] [23] [24] . Several Cx proteins are expressed in developing and mature skeletal tissues 19, 25, 26 . However, Cx43 is the major Cx protein expressed in chondrocytes, synovial cells and bone cells 10,12,27-29 and it has been involved in normal development and function of joint tissues 25, [30] [31] [32] , and in joint disorders including age-related bone loss 33 , rheumatoid arthritis 16, 34 and OA progression 10,12,25,27-29 .
During tissue regeneration and following injury, the dedifferentiation, redifferentiation and senescence processes play finely tuned temporal and spatial roles to reverse the loss of tissue in a precise way 35, 36 . Cx43, via channel-dependent and -independent functions, has been involved in different phases of tissue regeneration including in controlling acute and chronic inflammation, cell differentiation, migration, proliferation or cellular reprogramming and lately in cellular senescence [22] [23] [24] 37, 38 . Results from our lab and others, demonstrated that Cx43 is a target of interest for the treatment of OA in order to stop cartilage degradation and to restore regeneration. Overexpression of Cx43 and enhancement of the GJIC in osteoarthritic chondrocytes (OACs) compromise the ability of these cells to re-differentiate, promoting a stem-like state by activating the chondrocyte-mesenchymal transition factor Twist-1 and p53/p21mediated cellular senescence 4 . However we have recently demonstrated that this is a reversible loss, because downregulation of Cx43 reduces stemness, hypertrophy markers, senescence and therefore MMPs and proinflammatory mediators, and improves Col2A and proteoglycans' levels in monolayer and 3D cultures 4 .
Interestingly, this Cx43-sensitive circuit regulates joint inflammation, cellular plasticity and accumulation of senescent chondrocytes 4 . The downregulation of Cx43 in human osteoarthritic chondrocytes, using CRISPR technology and the GJ inhibitor carbenoxolone, restores chondrocyte redifferentiation and decreases the propensity of chondrocytes to undergo cellular senescence by downregulating Twist-1 and p53/p21/p16 and inhibiting the nuclear translocation of the master regulator of senescence secretory phenotype (SASP) NF-kB 4 . These results clearly indicate that Cx43 controls senescence and acts as a molecular switch in chondrocyte phenotypes within a wound healing process 4 . In fact, downregulation of Cx43 in different wound healing disorders halts disease progression by restoring tissue regeneration [39] [40] [41] [42] [43] .
In this study we describe the use of small molecules, based on olive phenolic compounds, to downregulate Cx43 in OA using 2D and human 3D cartilage models.
We have found that oleuropein decreases Cx43 promoter activity and GJIC, thus enhancing osteogenesis and chondrogenesis in hMSCs and redifferentiation of OACs. Besides, downregulation of Cx43 by olive-derived small polyphenols in OACs reduces cellular senescence in chondrocytes, bone and synovial cells and the inflammatory and catabolic activity related with cartilage degradation in OA. Thus, 6 these molecules by targeting Cx43 and senescence may be attractive candidates for tissue engineering and regenerative medicine strategies for OA treatment and for promotion of proper cartilage and joint repair in these patients.
Results.
Olive-derived polyphenols including oleuropein impair adipogenesis and enhance the chondrogenic and osteogenic ability of hMSCs. Cx43, altered during OA 27 , is also a critical regulator of hMSCs differentiation [44] [45] [46] . Based on previous reported results from our group 4, 27, 30, 47, 48 , we used a small-scale screening to identify compounds that downregulate Cx43 (data not shown), and we have identified compounds such as the small molecule oleuropein (Fig. 1a ). Oleuropein and an olive-extract (OE) containing 40% of oleuropein significantly reduced Cx43 protein levels in OACs treated with different concentrations for 2 hours, as detected by western-blot and by flow cytometry (Fig 1a) . Importantly, polyphenols comprising oleuropein have been previously proposed and patented for the treatment of OA due to their ability to stimulate cartilage anabolism and prevent inflammation [49] [50] [51] . An MTT assay showed no effect of 0.1, 1 or 10 µM oleuropein on the cell viability (O.D. 570 nm) of primary chondrocytes and hMSCs ( Fig. 1b ). We next examined hMSCs differentiation capacity in the presence of oleuropein (Fig. 1c, 1d and Supplementary   Fig. 1 ). In accordance with previous results 52 , oleuropein-treated hMSCs showed significantly less in adipogenic differentiation detected by oil red O for lipid staining and by peroxisome proliferator-activated receptor (PPARγ) gene expression, whereas osteogenesis, examined by alizarin red staining of calcium deposits and by osteocalcin (OSTCN) gene expression, was significantly increased ( Fig. 1c and Supplementary Fig. 1a and 1b ). Furthermore, a 3D micromass culture system using chondrogenic medium supplemented with 10 µM oleuropein or OE revealed an increase in ECM properties, reflecting a greater degree of chondrogenic differentiation within the 3D structure, with higher levels of Col2A1 deposited in the ECM and increased levels of aggrecan (ACAN) gene expression ( Fig. 1d and Supplementary Fig. 1c ). Remarkably decreased Cx43 gene expression was detected in hMSCs under the three differentiation conditions (adipogenesis, osteogenesis and chondrogenesis), this effect being more pronounced during chondrogenesis ( Supplementary Fig 2a) and in concordance with a previous report 53 (Fig. 1e and 1f ).
In this study, we have also observed changes in the Cx43 phosphorylation patterns at 7 and 14 days of chondrogenic differentiation by western blot (Fig. 1e ), which can 7 affect Cx43 stability and channel activity 54 . Different Cx43 phosphorylation patterns were also detected during adipogenesis and osteogenesis, suggesting differential regulation of Cx43 during hMSCs differentiation ( Supplementary Fig. 2b ). The treatment of hMSCs during chondrogenic differentiation with 10 µM oleuropein for 14 days caused an additional 1.7 fold reduction in Cx43 gene expression ( Fig. 1f ). In concordance with these results, OACs' differentiation (redifferentiation), for 7 days with chondrogenic medium supplemented with 10 µM oleuropein, led to a significant decrease in the Cx43 protein levels without impact on Cx43 phosphorylation patterns ( Fig. 1g ).
It is important to note that these results were obtained during differentiation of hMSCs under osteogenesis and chondrogenesis ( Fig. 1c -f) and dedifferentiated chondrocytes from patients (OACs) in normal and in chondrogenic medium ( Fig. 1a and Fig. 1g ). However, the treatment of undifferentiated hMSCs cultured in basal growth medium with oleuropein or OE for 2 hours increased Cx43 levels ( Supplementary Fig. 3a and 3b) and GJIC ( Supplementary Fig. 3c ), indicating that the effect of these olive derived polyphenols may be different depending on the cellular context.
Downregulation of Cx43 activity by oleuropein downregulates the EMT
transcription factor Twist-1 and enhances redifferentiation of OACs. Because oleuropein and the OE modulate Cx43 in OACs and the differentiation capacity of hMSCs, we expected that these compounds might modify de-and redifferentiation of OACs. Oleuropein treatment of primary chondrocytes isolated from patients with OA (OACs) decreased the Cx43 protein levels, as detected by western blot and flow cytometry ( Fig. 1a and Fig 1g) . We have previously found that intercellular coupling via GJ channels participates in the effects of Cx43 on the OAC phenotype 4 .
Interestingly, oleuropein modulation of Cx43 significantly reduced GJIC in OACs, as detected by scrape loading/dye uptake assay and flow cytometry analysis ( Fig. 2a ), but not in healthy chondrocytes, with dye transfer through GJ channels being more reduced in OACs than in healthy chondrocytes (Fig. 2b ). The decrease in Cx43 GJIC and protein levels were correlated with a significant reduction in the levels of the stemness markers CD105 and CD166 after 7 days in culture in presence of 10 µM oleuropein as detected by western-blot and flow cytometry ( Fig. 2c ). This result was consistent with our previous observations, where CD105 and CD166 stemness 8 markers were reduced when Cx43 was downregulated or when OACs were grown in chondrogenic medium to enhance redifferentiation for 14 days 4 . In fact, oleuropein effectively improved the phenotype of chondrocytes isolated from human OA cartilage grown in culture as a monolayer detected by Col2A1 levels and synthesis of proinflammatory mediators and MMP-3 ( Fig. 2d and 2e ). Treatment with 10 µM oleuropein for 2 h was enough to reduce overall Cx43 positivity and to increase Col2A1 protein levels ( Fig. 2d ) and decrease interleukin 6 (IL-6), COX-2, IL-1ß and MMP-3 gene expression ( Fig. 2e ).
Next, we sought to confirm whether oleuropein would target chondrocyte plasticity in 3D cultures. OACs were grown as a micromass pellet culture in chondrogenic medium supplemented with different concentrations of oleuropein ( Fig. 2f ). The enhancement of fully differentiated chondrocytes in chondrogenic medium improved the micromass matrix structure of OACs in 3D culture ( Fig. 2f ). Oleuropein and OE further decreased Cx43 levels ( Fig. 2g ) and further increased the deposition of proteoglycans detected by toluidine blue staining and Col2A1 detected by immunohistochemistry ( Fig. 2f ).
To further explore the effect of oleuropein on cell plasticity, OACs were grown in adipogenic medium in presence of 10 µM oleuropein. Notably, oleuropein significantly decreased the adipogenic differentiation of OACs ( Fig. 2h ). However, oleuropein treatment increased the osteogenic differentiation of OACs when these cells were grown in osteogenic medium with 10 µM oleuropein for 14 days ( Supplementary Fig. 4 ). Consistent with this finding, previous studies have suggested a direct transformation of mature chondrocytes into osteoblasts and osteocytes [55] [56] [57] , reemphasizing the effect of oleuropein as a modulator of cell plasticity in chondrocytes, enhancing OACs redifferentiation to mature chondrocytes (and transdifferentiation into bone cells).
Upregulation of Cx43 in OA involves dedifferentiation via chondrocyte-tomesenchymal transition (CMT) by Twist-1 activation, which was also reported in OA cartilage 4,58,59 . After oleuropein treatment, OACs showed a significant reduction in the nuclear localization of Twist-1 detected by western-blot of nuclear extracts (Fig. 2i ).
Furthermore, immunofluorescence assays showed that the nuclear localization of Twist-1 transcription factor in the presence of an arthritic insult (oligomycin), was attenuated when Cx43 protein levels were reduced by oleuropein treatment of OACs in monolayer culture (Fig. 2j ). In addition to Twist-1, oleuropein treatment in OACs led to a significant reduction of the expression of mesenchymal and EMT markers Ncadherin and vimentin ( Fig. 2k ).
Oleuropein modulates Cx43 gene promoter activity. Mechanisms that underlie the effects of oleuropein or the OE containing oleuropein and other small molecular polyphenols may be multifactorial. Yet, in chondrocytes decreased Cx43 protein levels were detected when OACs and the human chondrocyte cell line T/C-28a2 were treated with 10 µM oleuropein ( Fig. 1a and 3a ). However, changes in Cx43 protein levels were not evident when T/C-28a2 transfected with a vector to overexpress Cx43 was treated with 10 µM oleuropein (Fig. 3a, bottom ), suggesting that oleuropein in chondrocytes may affect Cx43 gene promoter activity rather than protein stability. We thus measured whether oleuropein affected the activity of the Cx43 gene promoter using a real-time reporter system. Human T/C-28a2 chondrocytes were transfected with a firefly luciferase reporter vector containing the regulatory regions of the Cx43 promoter and incubated for 1 h with 10 µM oleuropein and 5 µg/ml of the mitochondrial inhibitor oligomycin, which inhibits ATP synthase by blocking its proton channel 60, 61 and enhances Cx43 gene expression ( Fig. 2j, Fig 3b) .
In fact, this small molecule was previously used for in vitro and in vivo models of arthritis to induce inflammation and cartilage degradation 62 . Cx43 promoter activity (detected by luminescence) decreased after oleuropein treatment ( Fig. 3b ).
Oligomycin increased the luminescence signals, and the effect of oligomycin was significantly attenuated in the presence of oleuropein ( Fig. 3b ), which was correlated with the Cx43 mRNA levels detected by RT-qPCR ( Fig. 3b ). The luminescence signals strongly correlated with the effects of oleuropein and oligomycin on protein levels detected by immunofluorescence ( Fig. 3c ) and western blot ( Fig. 2j ) when OACs were grown in monolayer culture. These results indicate that oleuropein affects Cx43 (gene, GJA1) promoter activity, thus downregulating Cx43 protein levels ( Fig. 1a and Fig. 3a -c) and GJIC in OACs (Fig. 2b ).
Oleuropein enhances elimination of senescent cells. Senescent cells through
secretion of SASP promote dedifferentiation and reprogramming in neighbouring cells in the context of tissue injury 63, 64 . OACs treated with 10 µM oleuropein for 7 or 14 days in growth medium showed a significant reduction of senescent cells accumulated after 5 days of primary culture ( Fig. 4a ) and detected by betagalactosidase activity measured by flow cytometry (Fig. 4a ). Consistent with these models, Cx43 upregulation due to oligomycin insult (for 24 hours) significantly contributed to increase cellular senescence in OACs accumulated after 5 days in monolayer ( Fig. 4b, left) , whereas co-treatment with oleuropein significantly halted the accumulation of senescent cells, as measured by the quantitative flow cytometry analysis of beta-galactosidase activity (24 hours under treatments) ( Fig. 4b, left ) and beta-galactosidase staining (7 days under treatments) ( Fig. 4b, right) . Interestingly, increased levels of Cx43 were detected when the chondrocyte cell line T/C-28a2 was treated with 50 µg/mL of bleomycin for 24 h hours and the exposure to oleuropein for 24 hours, after bleomycin treatment, reduced both the number of senescent cells detected by ß-galactosidase activity and Cx43 protein levels detected by western-blot ( Supplementary Fig. 5 ). In concordance with these results, the treatment of OACs with 10 µM oleuropein for 2 hours led to a decrease in the levels of the senescence biomarker p16 INK4a (Fig. 4c ) and p53 and p21 protein levels ( Fig. 4d ). Cellular senescence and the senescence-associated secretory phenotype (SASP) convert senescent cells into proinflammatory cells by secreting factors such as IL-6 65, 66 .
Oleuropein reduced the accumulation of senescent cells and attenuated oligomycininduced SASP secretion detected by IL-6 and COX-2 gene expression in chondrocytes ( Fig. 4e ). This effect was also detected to a lesser extent for IL-1ß.
( Fig. 4e ). The secretory activity of senescent cells (SASP), including IL-6 gene expression can be activated by the master regulator of SASP, NF-κB 67, 68 .
Immunofluorescence assays showed that NF-κB (p65) activation detected by nuclear translocation in OACs by TNFα was diminished when cells were exposed to 10 µM oleuropein for 1 h (Fig. 4f ). Oleuropein also protected from the increase of Cx43 under TNFα treatment ( Fig. 4f, left) . Further, NF-κB nuclear translocation was partially abolished in OACs after 5 days in primary culture and treated with 10 µM oleuropein for only 2 hours and detected by western-blot (nuclear extracts) ( Fig. 4g ).
To further test the senolytic activity of oleuropein, synovial and bone cells isolated from synovium and spongy bone from joints from OA patients were treated with 10 µM oleuropein ( Fig. 4h -o) . We observed decreased Cx43 protein levels after only 2 hours under oleuropein exposure ( Fig. 4h and 4l ) together with a significant reduction in senescent cells accumulated after 5 days in primary culture and detected by ßgalactosidase activity ( Fig. 4i and 4m ) and confirmed by RT-qPCR to test the expression of the senescence biomarker p16 INK4a (Fig. 4j and 4n ) and the synthesis of the SASP factors IL1-ß, COX-2 and IL-6 ( Fig. 4k and 4o ).
Discussion.
Chondrocyte phenotypic changes are common response to insults and during OA progression 4 . Previous data reported by our group demonstrate that downregulation of Cx43 improves cell phenotype protecting chondrocytes from dedifferentiation (via EMT transcription factors such as Twist-1) and senescence (via p53 activation) 4 .
Although oleuropein was reported to protect from OA progression [69] [70] [71] [72] [73] , there was no solid evidence about the underlying molecular mechanisms involved in this effect.
Our results are consistent with previous studies showing the protective effect of oleuropein and olive derived polyphenols in OA 69, 71 and that Cx43 downregulation have significant effects on chondrocyte phenotype 4, 16, 30 . In our study, we show that oleuropein modulates the activity of the Cx43 gene promoter, reducing Cx43 and GJIC in OACs and hMSCs. Indeed, our data indicate that downregulation of Cx43 by oleuropein in OACs in 3D and monolayer culture improves cell phenotype by protecting chondrocytes from the EMT transcription factor Twist-1 activation under experimental insults and from accumulation of senescent cells ( Fig. 2 and Fig. 4 ). This is the first study that demonstrated one of the potential mechanisms of oleuropein in OACs, synovial and bone cells ( and is a potent antioxidant agent with anti-tumour and anti-inflammatory properties 82, 83 . The mechanism of action this polyphenol is under study 82 , and show that oleuropein and its major metabolite hydroxytyrosol have antioxidant activity by inhibition and/or scavenging of ROS 84, 85 , which has been suggested to reduce NF-kB activation [86] [87] [88] [89] . Other mechanistic studies implicate nitric oxide (NO) production [89] [90] [91] [92] or autophagy and inhibition of the mammalian target of rapamycin (mTOR) [93] [94] [95] . Here, we show that oleuropein directly regulates Cx43 gene promoter activity leading to downregulation of GJIC ( Fig. 2a and Fig. 3b ). Interestingly, in hMSCs oleuropein reduces Cx43 and GJIC only under differentiation processes and increases Cx43 in undifferentiated hMSCs (Fig 1e, 1f, Supplementary Fig. 2 and Supplementary Fig. 3) .
These results indicate that the activity of this molecule in the Cx43 gene promoter depends on the context. In fact, a gene expression profiling study has suggested that oleuropein affects the expression of multiple genes involved in oxidative stress, inflammation, fibrosis, cell proliferation and differentiation among others 96 , which implies that the mechanisms that underlie the beneficial effects of this molecule may be multifactorial and depend on the conditions 96 . These observations emphasize the importance of Cx43-mediated effects of oleuropein specifically during the differentiation process. Also, our results show that the effects of oleuropein are often equal or even smaller than those of olive extract that contains 41.5% of oleuropein at equivalent doses. This observation suggests that other polyphenols or compounds, such as the hydroxytyrosol, may synergize with oleuropein activity in chondrocytes 97, 98 . On the other hand, the treatment of hMSCs with oleuropein or OE, in chondrogenic, osteogenic or adipogenic differentiation medium leads to downregulation of Cx43 and GJIC, enhancing osteogenesis and chondrogenesis, but reducing adipogenesis. This differential sensitivity of hMSCs to oleuropein and OE may have potential applications in preventive and regenerative medicine in other bone and cartilage disorders e.g. by reducing ectopic adipocyte accumulation in bone marrow cavities and improving osteogenesis during bone repair [99] [100] [101] .
Our data show decreased Cx43 levels with decreased GJ activity in the presence of oleuropein in OACs and in differentiating hMSCs, but increased Cx43 levels with increased GJIC in undifferentiated hMSCs, suggesting that the effect of this molecule on GJIC depends on its effect on Cx43 levels (or subcellular localization). In fact, phosphorylation of Cx43 affects protein stability and GJIC activity 54,102,103 and we have detected changes in Cx43 phosphorylation pattern during hMSCs differentiation (chondrogenesis, osteogenesis and adipogenesis) but not under oleuropein treatment (in hMSCs and OACs) indicating that oleuropein affects Cx43 levels more than protein or gap junction plaque stability or regulation of the activity of these intercellular channels. Further, Cx43 channel-independent activities involve its signalling hub's ability to recruit proteins to the membrane 24,104-106 or its ability to control gene transcription by nuclear translocation and binding to RNA polymerase II and gene promoters 107 . We have recently reported that overactivity of Cx43 in OACs compromise the ability of these cells to redifferentiate by maintaining the stem-like 13 state enhanced by Twist-1 activity and tissue remodelling and proinflammatory agents such as IL-1ß 4 . Here, we show that oleuropein restores chondrocyte phenotype detected by reduced levels of the stem-markers CD105, CD166, N-cad and vimentin (Fig. 2c, 2k ). The effect of oleuropein in chondrocyte plasticity correlated with activation of redifferentiation via downregulation of Cx43 and Twist-1 ( Fig.2i, 2j, 2k) , leading to increased levels of proteoglycans and Col2A1 together with a decrease in the levels of inflammatory cytokines and metalloproteinases such as IL-1ß and MMP-3 ( Fig. 2d, 2e, 2f ).
In cell culture and in osteoarthritic cartilage, OACs undergo dedifferentiation and senescence 4,108,109 . Elimination of senescent cells in vivo using the senolytic drug UBX0101 has been demonstrated to improve cartilage regeneration after articular joint injury in mice 3 . Here we show that oleuropein reduces cellular senescence in OACs, synovial and bone cells in monolayer and protects from accumulation of senescent cells under an arthritic insult (Fig. 4a, 4b, 4i and 4m ). NF-kB has been shown to cooperatively regulate the inflammatory components of the SASP, together with other factors 68, [110] [111] [112] . In this study the reduction of senescence is accompanied by reduced activity of the NF-kB transcription factor and therefore reduced synthesis of SASP including those encoding IL-6, IL-1ß and COX-2 ( Fig. 4e) . Notably, these components enhance inflammation, senescence and activate dedifferentiation and Cellular reprogramming, dedifferentiation via EMT and senescence play active roles during tissue regeneration 116 . These processes are activated in response to damage and involve dedifferentiation, reprogramming, inflammation and ECM remodelling and resolve with redifferentiation and elimination of senescent cells 116 . Accumulation of dedifferentiated (stem-like cells) and senescent cells leads to impaired tissue regeneration and fibrosis with loss of tissue function 117, 118 (Fig. 5 ). Understanding and manipulating the complex Cx43 signalling appears to be very challenging but would expand our opportunities for modulating wound-healing related disorders such as OA. So far, our results indicate that molecules that reduce Cx43 levels in OA such as oleuropein will potentially restore cartilage repair in OA by activating chondrocyte redifferentiation and by eliminating senescent cells, contributing to creating a regeneration-permissive environment in OA patients.
Consistent with previous studies, oleuropein shows a potent senolytic and antiinflammatory effect by reducing IL-1ß, IL-6 and COX-2 gene expression and NF-kB activation 119 . Our study is the first to demonstrate the effect of this polyphenol on Cx43 activity and senescence. Our results show that oleuropein downregulates Cx43 in OACs, enhancing chondrocyte redifferentiation, together with a decrease in cellular senescence and SASP activated by NF-kB ( Fig. 5) . Besides, modulation of Cx43 by oleuropein shifts the hMSCs differentiation capacity towards osteogenic and chondrogenic lineages, while decreasing adipogenic differentiation. These effects may be useful in cell therapy approaches that aim to promote cartilage and bone regeneration because the osteogenesis/adipogenesis switch has been associated with different bone disorders characterized by reduced bone formation and increased bone marrow fat accumulation 99, 100 . Altogether, these findings indicate that oleuropein controls Cx43 gene expression and acts as a potent senolytic drug that may serve as a potential agent to improve both the effectiveness of stem cell therapy and cartilage and joint regeneration in patients to stop OA progression, by restoring tissue regeneration.
Experimental procedures.
Tissue collection, processing and cell culture. Collection and processing of cartilage from human knees and femoral heads from adult donors undergoing joint surgery were performed as previously described 28 . The study was conducted with the approval of the institutional ethics committee (C.0003333, 2012/094 & 2015/029) after the acquisition of the signed informed consents. Samples from healthy, moderate OA (grades I-II) and high OA (grades III-IV) groups were selected for this study, which were classified according to their medical record data and histological analysis, as previously described 27 . 25 human samples were used for this study.
Each experiment was conducted with at least three different patients/samples. Primary chondrocytes, isolated from fresh cartilage as previously described 28 which were allowed to transfer the dye for 3 min at 37°C. LY transfer was evaluated in a Nikon Eclipse Ti fluorescent microscope, and the number of dye-positive cells (LY transfer) from the cut site to the farthest detectable uptake of LY reflects the GJ connectivity between cells. The score was calculated as previously reported 120, 121 . 
GJ connectivity by flow cytometry. Equal numbers of cells were incubated

